Introduction
Some clinical observations have suggested that bacterial vaginosis is a sexually transmitted disease.l-4 It has also been suggested that, in cases of symptomatic bacterial vaginosis, treatment of the sexual partner may reduce the risk of recurrence, which ranges from about 5% to 20%. However, the data on the efficacy of treating the partner are scanty and controversial.8 12 In three studies no relation emerged between oral therapy of the partner and recurrence rate.8-10 A recent well designed trial with a large sample size showed the utility of treating the male" in reducing the recurrence of bacterial vaginosis. In these trials, the partner was treated with oral metronidazole, at different dosages, 8-1" or tinidazole.9 In controlled trials, oral clindamycin has been shown to be as effective as oral metronidazole, or more so, in the treatment of bacterial vaginosis."3 Systemic metronidazole causes nausea, a bitter taste in the mouth, rarely, peripheral neuropathy, and interacts with alcohol ingestion. In addition, metronidazole may cause malformations during pregnancy, so its use must be discouraged in fertile women. '4 We tested the efficacy of treatment with clindamycin of the partner on the recurrence rate within 3 months from diagnosis and treatment of bacterial vaginosis. Patients The end point of the study was to compare the recurrence rate 12 weeks after bacterial vaginosis in women whose sexual partner was treated with oral clindamycin or placebo. We planned to include about 150 patients. This sample size would give a high probability (,p = 0.80) of detection, at a reasonable level of statistical significance (a = 0.05) of a decreased probability of recurrence, from 30% in women whose partner was treated with placebo to 10% in women whose partner was treated with clindamycin.
For the intention to treat evaluation, any patient not cured after vaginal treatment with clindamycin, with medical events or lost during the treatment period, was considered a "nonresponder". In the efficacy analysis we considered only women cured at the first week's visit, who completed the study according to the protocol. The difference in the frequency of recurrences between the two groups was analysed using the X2 test.
Results Table 1 shows the characteristics of couples randomised to the two groups. There was good comparability in terms of baseline characteristics of women and their partners, including age, weight, marital status, mean numbers of sexual intercourse during the 3 months before study entry, interval from last sexual intercourse, history of genital infections, including previous episodes of bacterial vaginosis in women and urethritis in men. Further, the use of contraceptive methods was similar in women randomised to clindamycin and in the placebo group.
No important difference emerged between the study groups in self reported numbers of sexual intercourse during the study period. Two women reported a new untreated partner during the follow up period. Table 2 shows the frequency of "cure" 7 days after start of treatment with clindamycin vaginal cream. Overall, 131 women out of the 139 who entered the study were cured (94-2%, lower 95% confidence interval 79.8, based on Poisson's approximation). There was no difference in the cure rate among women whose Treatment of male partners and recurrence of bacterial vaginosis: a randomised trial Table 3 .
Recurrence rate was similar in the two groups 4 weeks after start of treatment. According to the intention to treat analysis recurrence/persistence was observed in nine (13.0%) out of the 69 women whose partner received clindamycin and in eight (11 4%) out of the 70 who received placebo. Table 4 shows the frequency of recurrence at 12 weeks according to the intention to treat analysis. Of the 69 women whose partner received clindamycin, 22 (31.9%) reported "recurrence"' or persistence. The corresponding number was 21 (30%) out of the 70 women whose partner received placebo.
Of the 84 couples in which the woman was cured at the first week's visit and who completed the study, there were five recurrences (11-6%) among the 43 women whose partner received clindamycin and nine (22.0%) of the 41 whose partner received placebo (X2 p = not significant).
No difference emerged between the two groups in the recurrence rates at 4 and 8 weeks according to the intention to treat analysis (data not shown).
Local burning was reported by two women after treatment with clindamycin vaginal cream. Gastrointestinal symptoms were reported by seven men randomised to clindamycin and four randomised to placebo. Discussion Before discussing the results of this study potential limitations should be considered. The first is the large number of couples who withdrew from the study. However, the dropout rates and the causes for withdrawal were similar in the two groups. Another potential limitation is the small sample size. In fact, we were able to identify only a decrease in the frequency of recurrence in the partner's treatment group of 20%, to detect a difference of 10% in the recurrence rate the study would have to include about 600 patients.
To take these limitations into account and obtain a conservative evaluation of treatment efficacy, we have presented the intention to treat analysis that considers as treatment failures all subjects for whom no information on recurrence was available. We also decided to present the main analysis according to the intention to treat modality since we were interested in assessing the efficacy of male treatment in routine clinical practice. However, results were similar when the analysis included only couples who ended the study and respected the protocol. Other bias should not markedly affect the results. The same treatment schemes and criteria for assessing response were used in the collaborating centres. The clinicians were blind to the study treatment.
The cure rate of bacterial vaginosis after 1 week's vaginal treatment with clindamycin was high, about 95%. This is consistent with, or even better than, the results of previous studies with this drug in bacterial vaginosis. For example, in a large international study conducted in Germany, Austria, and Switzerland, comparing oral metronidazole and vaginal clindamycin and including more than 400 women with bacterial vaginosis, the cure or improvement rate 1 month after therapy was 83% in the clindamycin group.'6 Other studies reported response rates ranging from 60% to 95%i.17 20 In this study we used clindamycin instead of metronidazole or its derivatives. Male treatment did not markedly reduce the recurrence rate of bacterial vaginosis. As previously discussed, owing to the low power of this study we were able to identify a marked difference in the recurrence rate between the two groups, although less marked reduction (as for example of about 10%) may have clinical relevance.
With regard to safety, the treatment was generally well tolerated. The frequency of adverse events was higher in the placebo group than in the clindamycin group. Gastrointestinal disorders, the most common adverse events of oral clindamycin, were only slightly more frequent in the clindamycin group than in the placebo group.
In conclusion, this study confirms that vaginal clindamycin is effective and safe in the treatment of bacterial vaginosis. The findings, however, give no support to the suggestion that male treatment markedly reduces the short term recurrence rate.
